ReviewInternational journal of molecular sciences2025
6-Prenylnaringenin-Its Beneficial Biological Effects and Possible Applications.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biological Activity of Hops (Nutrients · 2026Review
- Nutritional Impact on Breast Cancer in Menopausal and Post-Menopausal Patients Treated with Aromatase Inhibitors.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
6-Prenylnaringenin (6-PN) is a natural compound which occurs in some plants, but the primary dietary source for humans is beer. This compound exhibits broad and potent antimicrobial, anticancer, and neuroactive properties, and weak estrogenic effects. Currently, hop extracts standardized for 6-PN content (relative to other prenylflavonoids) are commercially available and utilized in the non-hormonal treatment of menopause. It is probable that in the future, 6-PN will be employed in the prevention or treatment of non-hormone-dependent cancers and infectious diseases, as well as a sedative, hypnotic, and analgesic agent. Further research is essential to precisely determine the exact mechanisms of action of 6-PN and, critically, to leverage its unique therapeutic profile. This review synthesizes current evidence, highlighting that 6-PN warrants priority investigation as a core scaffold for novel drug development, particularly as a GABA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.